{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:43:55Z","timestamp":1790315035511,"version":"4.1.0"},"reference-count":117,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007316","name":"National Cancer Institute Division of Cancer Prevention","doi-asserted-by":"publisher","award":["U01 CA271887"],"award-info":[{"award-number":["U01 CA271887"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"National Cancer Institute Division of Cancer Prevention","doi-asserted-by":"publisher","award":["U01 CA283935"],"award-info":[{"award-number":["U01 CA283935"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"National Cancer Institute Division of Cancer Prevention","doi-asserted-by":"publisher","award":["U01 DK130113"],"award-info":[{"award-number":["U01 DK130113"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007316","name":"National Cancer Institute Division of Cancer Prevention","doi-asserted-by":"publisher","award":["R01 CA256977"],"award-info":[{"award-number":["R01 CA256977"]}],"id":[{"id":"10.13039\/100007316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"German Research Foundation","doi-asserted-by":"publisher","award":["493345156"],"award-info":[{"award-number":["493345156"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008538","name":"PSC Partners Seeking a Cure","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008538","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PMP22\/00054"],"award-info":[{"award-number":["PMP22\/00054"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Carlos III Health Institute","doi-asserted-by":"publisher","award":["PI24\/00148"],"award-info":[{"award-number":["PI24\/00148"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"publisher","award":["70114101"],"award-info":[{"award-number":["70114101"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["PRYGN246692BANA"],"award-info":[{"award-number":["PRYGN246692BANA"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jhep.2026.03.040","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:36:35Z","timestamp":1782992195000},"page":"683-694","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The future of blood-based biomarkers in liver cancer"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1172-3971","authenticated-orcid":false,"given":"Amit G.","family":"Singal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4857-4276","authenticated-orcid":false,"given":"Anna","family":"Saborowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neehar D.","family":"Parikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus M.","family":"Banales","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2026.03.040_bib1","article-title":"Liver cancer in 2021: global burden of disease study","author":"Tan","year":"2024","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.040_bib2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cgh.2020.09.036","article-title":"Conceptual model for the hepatocellular carcinoma screening continuum: current status and research Agenda","volume":"20","author":"Singal","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.040_bib3","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/jnci\/djae228","article-title":"Benefits and harms of hepatocellular carcinoma screening outreach in patients with cirrhosis: a multi-center randomized clinical trial","volume":"117","author":"Singal","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2026.03.040_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102755","article-title":"Cost-effectiveness of a precision hepatocellular carcinoma surveillance strategy in patients with cirrhosis","volume":"75","author":"Kao","year":"2024","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.040_bib5","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.cgh.2020.09.015","article-title":"Provider attitudes toward risk-based hepatocellular carcinoma surveillance in patients with cirrhosis in the United States","volume":"20","author":"Kim","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.040_bib6","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.040_bib7","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","year":"2024","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.040_bib8","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/hep.32779","article-title":"Risk stratification and early detection biomarkers for precision HCC screening","volume":"78","author":"Lee","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.040_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2023.02.022","article-title":"International liver cancer association (ILCA) white paper on hepatocellular carcinoma risk stratification and surveillance","author":"Singal","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.040_bib10","article-title":"Hepatocellular carcinoma risk scores for non-viral liver disease: a systematic review and meta-analysis","volume":"7","author":"Burke","year":"2025","journal-title":"JHEP Rep"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.040_bib11","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jhep.2021.09.009","article-title":"Comparative performance of risk prediction models for hepatitis B-related hepatocellular carcinoma in the United States","volume":"76","author":"Kim","year":"2022","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.040_bib12","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.040_bib13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score","volume":"12","author":"Yang","year":"2011","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.jhep.2026.03.040_bib14","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/apt.14937","article-title":"Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases","volume":"48","author":"Stine","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2026.03.040_bib15","article-title":"Veterans Analysis of Liver Disease group of i. Use of liver stiffness measurement for HCC risk stratification in metabolic dysfunction-associated steatotic liver disease","author":"John","year":"2025","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.jhep.2026.03.040_bib16","first-page":"836","article-title":"A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis","volume":"2","author":"Fujiwara","year":"2021","journal-title":"Med (N Y)"},{"issue":"650","key":"10.1016\/j.jhep.2026.03.040_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abo4474","article-title":"Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease","volume":"14","author":"Fujiwara","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jhep.2026.03.040_bib18","article-title":"Phase 3 validation of prognostic liver secretome signature with alpha-fetoprotein plus age, male sex, albumin-bilirubin, and platelets for hepatocellular carcinoma risk stratification in cirrhosis","author":"Fujiwara","year":"2024","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.040_bib19","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.jhep.2020.11.024","article-title":"Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores","volume":"74","author":"Bianco","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.040_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282309","article-title":"Risk stratification for hepatocellular cancer among patients with cirrhosis using a hepatic fat polygenic risk score","volume":"18","author":"Thrift","year":"2023","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.040_bib21","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/s41598-017-00631-9","article-title":"A circulating MicroRNA signature capable of assessing the risk of hepatocellular carcinoma in cirrhotic patients","volume":"7","author":"Huang","year":"2017","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.jhep.2026.03.040_bib22","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1093\/carcin\/bgx078","article-title":"Plasma DNA methylation marker and hepatocellular carcinoma risk prediction model for the general population","volume":"38","author":"Wu","year":"2017","journal-title":"Carcinogenesis"},{"issue":"7","key":"10.1016\/j.jhep.2026.03.040_bib23","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/S1470-2045(15)00048-0","article-title":"A serum microRNA classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study","volume":"16","author":"Lin","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.040_bib24","doi-asserted-by":"crossref","DOI":"10.1111\/liv.70049","article-title":"Mutational analysis of bile cell-free DNA in primary sclerosing cholangitis: a pilot study","volume":"45","author":"Arechederra","year":"2025","journal-title":"Liver Int"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.040_bib25","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jhep.2023.02.027","article-title":"Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma","volume":"79","author":"Lapitz","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.040_bib26","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jhep.2022.01.023","article-title":"HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: a meta-analysis","volume":"77","author":"Singal","year":"2022","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.jhep.2026.03.040_bib27","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00432-004-0552-0","article-title":"Randomized controlled trial of screening for hepatocellular carcinoma","volume":"130","author":"Zhang","year":"2004","journal-title":"J Cancer Res Clin Oncol"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.040_bib28","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/apt.16779","article-title":"Association between ultrasound quality and test performance for HCC surveillance in patients with cirrhosis: a retrospective cohort study","volume":"55","author":"Chong","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.040_bib29","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.31309","article-title":"Use of hepatocellular carcinoma surveillance in patients with cirrhosis: a systematic review and meta-analysis","volume":"73","author":"Wolf","year":"2021","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.040_bib30","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1053\/j.gastro.2018.01.064","article-title":"Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis","volume":"154","author":"Tzartzeva","year":"2018","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.040_bib31","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.2214\/AJR.21.26735","article-title":"Associations of ultrasound LI-RADS visualization score with examination, sonographer, and radiologist factors: retrospective assessment in over 10,000 examinations","volume":"218","author":"Fetzer","year":"2022","journal-title":"AJR Am J Roentgenol"},{"issue":"7","key":"10.1016\/j.jhep.2026.03.040_bib32","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1053\/j.gastro.2021.01.233","article-title":"International liver cancer association (ILCA) white paper on biomarker development for hepatocellular carcinoma","volume":"160","author":"Singal","year":"2021","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.040_bib33","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.cgh.2021.08.011","article-title":"Decreasing trend of serum alpha-fetoprotein level in hepatocellular carcinoma","volume":"20","author":"Vipani","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.03.040_bib34","article-title":"Addition of AFP improves sensitivity of ultrasound for early-stage HCC detection in patients with cirrhosis","author":"Patel","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.040_bib35","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep4.1847","article-title":"Multimarker panels for detection of early stage hepatocellular carcinoma: a prospective, multicenter, case-control study","volume":"6","author":"Piratvisuth","year":"2022","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.040_bib36","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1159\/000547895","article-title":"Performance of GALAD, GAAD, and ASAP for early HCC detection in chronic liver disease: a systematic review and meta-analysis","volume":"15","author":"Jarrah","year":"2025","journal-title":"Liver Cancer"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.040_bib37","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1053\/j.gastro.2024.09.008","article-title":"A phase 3 biomarker validation of GALAD for the detection of hepatocellular carcinoma in cirrhosis","volume":"168","author":"Marsh","year":"2025","journal-title":"Gastroenterology"},{"issue":"11","key":"10.1016\/j.jhep.2026.03.040_bib38","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000565","article-title":"National liver cancer screening trial (TRACER) study protocol","volume":"8","author":"Singal","year":"2024","journal-title":"Hepatol Commun"},{"issue":"12","key":"10.1016\/j.jhep.2026.03.040_bib39","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1136\/gutjnl-2019-318882","article-title":"Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma","volume":"68","author":"Cai","year":"2019","journal-title":"Gut"},{"issue":"S11","key":"10.1016\/j.jhep.2026.03.040_bib40","article-title":"A prospective, blinded, multicenter U.S. evaluation of a multianalyte blood-based test for the detection of hepatocellular carcinoma (HCC) in patients with cirrhosis","volume":"80","author":"Taggart","year":"2024","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.040_bib41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.cgh.2021.08.010","article-title":"Validation of a novel multitarget blood test shows high sensitivity to detect early stage hepatocellular carcinoma","volume":"20","author":"Chalasani","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"S1","key":"10.1016\/j.jhep.2026.03.040_bib42","article-title":"Performance of a multi-target blood test versus ultrasound in detecting early hepatocellular carcinoma: results from the ALTUS prospective study","volume":"82","author":"John","year":"2025","journal-title":"Hepatology"},{"issue":"S1","key":"10.1016\/j.jhep.2026.03.040_bib43","first-page":"S1995","article-title":"Novel multiomics biomarker signature derived from blood circulating hepatocyte-extracellular vesicles for the early detection of HCC","volume":"80","author":"Figueiras","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.040_bib44","article-title":"Unannotated small RNA clusters associated with circulating extracellular vesicles detect early stage liver cancer","author":"von Felden","year":"2021","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.040_bib45","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/hep.32692","article-title":"HCC EV ECG score: an extracellular vesicle-based protein assay for detection of early-stage hepatocellular carcinoma","volume":"77","author":"Sun","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.040_bib46","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2159-8290.CD-22-0659","article-title":"Detecting liver cancer using cell-free DNA fragmentomes","volume":"13","author":"Foda","year":"2023","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.040_bib47","article-title":"Metabolomic liquid biopsy dynamics predict early-stage HCC and actionable candidates of human hepatocarcinogenesis","volume":"7","author":"Schulze","year":"2025","journal-title":"JHEP Rep"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.040_bib48","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/hep.32771","article-title":"AASLD practice guidance on primary sclerosing cholangitis and cholangiocarcinoma","volume":"77","author":"Bowlus","year":"2023","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.040_bib49","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.jhep.2022.05.011","article-title":"EASL clinical practice guidelines on sclerosing cholangitis","volume":"77","year":"2022","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.040_bib50","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/hep.29730","article-title":"Surveillance for hepatobiliary cancers in patients with primary sclerosing cholangitis","volume":"67","author":"Ali","year":"2018","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.040_bib51","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.cgh.2011.02.007","article-title":"Many patients with primary sclerosing cholangitis and increased serum levels of carbohydrate antigen 19-9 do not have cholangiocarcinoma","volume":"9","author":"Sinakos","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.03.040_bib52","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.12659\/MSM.895040","article-title":"Diagnostic accuracy of serum CA19-9 in patients with cholangiocarcinoma: a systematic review and meta-analysis","volume":"21","author":"Liang","year":"2015","journal-title":"Med Sci Monit"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.040_bib53","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jhep.2025.03.007","article-title":"EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma","volume":"83","year":"2025","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.jhep.2026.03.040_bib54","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000751","article-title":"The incidence and predictors of false-negative pancreatobiliary fluorescence in situ hybridization (PB-FISH) in biliary strictures: a prospective study","volume":"9","author":"Aggarwal","year":"2025","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.040_bib55","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jhep.2022.11.011","article-title":"Prospective surveillance for cholangiocarcinoma in unselected individuals with primary sclerosing cholangitis","volume":"78","author":"Villard","year":"2023","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.040_bib56","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030721","article-title":"Patients with cholangiocarcinoma present specific RNA profiles in serum and urine extracellular vesicles mirroring the tumor expression: novel liquid biopsy biomarkers for disease diagnosis","volume":"9","author":"Lapitz","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.040_bib57","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jhep.2017.02.024","article-title":"Cancer-associated circulating large extracellular vesicles in cholangiocarcinoma and hepatocellular carcinoma","volume":"67","author":"Julich-Haertel","year":"2017","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.jhep.2026.03.040_bib58","doi-asserted-by":"crossref","first-page":"3103","DOI":"10.1111\/liv.14585","article-title":"Synergistic effects of extracellular vesicle phenotyping and AFP in hepatobiliary cancer differentiation","volume":"40","author":"Urban","year":"2020","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.040_bib59","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/hep.30319","article-title":"Serum metabolites as diagnostic biomarkers for cholangiocarcinoma, hepatocellular carcinoma, and primary sclerosing cholangitis","volume":"70","author":"Banales","year":"2019","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.040_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061644","article-title":"Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: a machine-learning approach","volume":"12","author":"Urman","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.040_bib61","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1002\/ijc.34356","article-title":"Blood-based tumor fibrosis markers as diagnostic and prognostic biomarkers in patients with biliary tract cancer","volume":"152","author":"Christensen","year":"2023","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.040_bib62","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jhep.2022.05.036","article-title":"Whole blood microRNAs capture systemic reprogramming and have diagnostic potential in patients with biliary tract cancer","volume":"77","author":"Hogdall","year":"2022","journal-title":"J Hepatol"},{"issue":"13","key":"10.1016\/j.jhep.2026.03.040_bib63","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133222","article-title":"Next-generation biomarkers for cholangiocarcinoma","volume":"13","author":"Rodrigues","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.040_bib64","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1477-2574.2009.00128.x","article-title":"Alpha-fetoprotein and tumour size are associated with microvascular invasion in explanted livers of patients undergoing transplantation with hepatocellular carcinoma","volume":"12","author":"McHugh","year":"2010","journal-title":"HPB (Oxford)"},{"issue":"34","key":"10.1016\/j.jhep.2026.03.040_bib65","doi-asserted-by":"crossref","first-page":"5734","DOI":"10.1200\/JCO.2009.23.1282","article-title":"Alpha-fetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival","volume":"27","author":"Riaz","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.040_bib66","doi-asserted-by":"crossref","DOI":"10.3390\/v14040775","article-title":"Alpha-fetoprotein (AFP) and AFP-L3 is most useful in detection of recurrence of hepatocellular carcinoma in patients after tumor ablation and with low AFP level","volume":"14","author":"Force","year":"2022","journal-title":"Viruses"},{"issue":"8","key":"10.1016\/j.jhep.2026.03.040_bib67","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/lt.23904","article-title":"Alpha-fetoprotein level > 1000 ng\/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria","volume":"20","author":"Hameed","year":"2014","journal-title":"Liver Transpl"},{"issue":"11","key":"10.1016\/j.jhep.2026.03.040_bib68","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/j.1872-034X.2011.00858.x","article-title":"Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively","volume":"41","author":"Kobayashi","year":"2011","journal-title":"Hepatol Res"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.040_bib69","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jhep.2008.04.013","article-title":"Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC","volume":"49","author":"Toyoda","year":"2008","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.jhep.2026.03.040_bib70","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1002\/(SICI)1097-0142(19961115)78:10<2094::AID-CNCR9>3.0.CO;2-O","article-title":"Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma","volume":"78","author":"Shimada","year":"1996","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.040_bib71","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.gastha.2023.11.018","article-title":"Alpha-fetoprotein, alpha-fetoprotein-L3, and des-gamma-carboxy prothrombin stratify hepatocellular carcinoma treatment response and progression risk","volume":"3","author":"Nunez","year":"2024","journal-title":"Gastro Hep Adv"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.040_bib72","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.jhep.2023.08.020","article-title":"AFP-L3 and DCP strongly predict early hepatocellular carcinoma recurrence after liver transplantation","volume":"79","author":"Norman","year":"2023","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.jhep.2026.03.040_bib73","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1038\/nmat4997","article-title":"Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma","volume":"16","author":"Xu","year":"2017","journal-title":"Nat Mater"},{"issue":"10","key":"10.1016\/j.jhep.2026.03.040_bib74","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1038\/sj.bjc.6604034","article-title":"Circulating cell-free DNA as a predictive marker for distant metastasis of hepatitis C virus-related hepatocellular carcinoma","volume":"97","author":"Tokuhisa","year":"2007","journal-title":"Br J Cancer"},{"issue":"14","key":"10.1016\/j.jhep.2026.03.040_bib75","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14143367","article-title":"Circulating cell-free DNA profiling predicts the therapeutic outcome in advanced hepatocellular carcinoma patients treated with combination immunotherapy","volume":"14","author":"Matsumae","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.040_bib76","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.jhep.2021.12.010","article-title":"Cholangiocarcinoma landscape in Europe: diagnostic, prognostic and therapeutic insights from the ENSCCA Registry","volume":"76","author":"Izquierdo-Sanchez","year":"2022","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.040_bib77","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/hep.27944","article-title":"Circulating tumor cells are associated with poor overall survival in patients with cholangiocarcinoma","volume":"63","author":"Yang","year":"2016","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.jhep.2026.03.040_bib78","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S1470-2045(15)00050-9","article-title":"Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial","volume":"16","author":"Zhu","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.040_bib79","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.jhep.2026.03.040_bib80","doi-asserted-by":"crossref","first-page":"4848","DOI":"10.1158\/1078-0432.CCR-20-4219","article-title":"Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: from the phase III REFLECT study","volume":"27","author":"Finn","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.jhep.2026.03.040_bib81","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/s41591-022-01868-2","article-title":"Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.040_bib82","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1007\/s12072-024-10680-8","article-title":"Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma","volume":"18","author":"Chuma","year":"2024","journal-title":"Hepatol Int"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.040_bib83","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41388-020-01519-1","article-title":"Mutations in circulating tumor DNA predict primary resistance to systemic therapies in advanced hepatocellular carcinoma","volume":"40","author":"von Felden","year":"2021","journal-title":"Oncogene"},{"issue":"8","key":"10.1016\/j.jhep.2026.03.040_bib84","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid"},{"issue":"10391","key":"10.1016\/j.jhep.2026.03.040_bib85","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.040_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104003","article-title":"EGCEa. ESMO Clinical Practice Guideline interim update on the management of biliary tract cancer","volume":"10","author":"Vogel","year":"2025","journal-title":"ESMO Open"},{"issue":"12","key":"10.1016\/j.jhep.2026.03.040_bib87","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.annonc.2022.09.150","article-title":"The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer","volume":"33","author":"Berchuck","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jhep.2026.03.040_bib88","article-title":"Clinical utility and prognostic implications of circulating cell-free DNA in biliary tract cancer","volume":"9","author":"Cowzer","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.040_bib89","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.jhep.2024.10.020","article-title":"Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer","volume":"82","author":"Hwang","year":"2025","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.040_bib90","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-49860-0","article-title":"Genotyping of circulating tumor DNA in cholangiocarcinoma reveals diagnostic and prognostic information","volume":"9","author":"Ettrich","year":"2019","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.040_bib91","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.annonc.2024.11.017","article-title":"Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling","volume":"36","author":"Goyal","year":"2025","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.jhep.2026.03.040_bib92","doi-asserted-by":"crossref","first-page":"4491","DOI":"10.1158\/1078-0432.CCR-23-3780","article-title":"Clinical value of liquid biopsy in patients with FGFR2 fusion-positive cholangiocarcinoma during targeted therapy","volume":"30","author":"Gonzalez-Medina","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.jhep.2026.03.040_bib93","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/1078-0432.CCR-23-2693","article-title":"Circulating tumor DNA enables sensitive detection of actionable gene fusions and rearrangements across cancer types","volume":"30","author":"Kasi","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.040_bib94","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","article-title":"EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma","volume":"79","year":"2023","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.040_bib95","article-title":"Diagnostic and prognostic value of circulating cell-free DNA for cholangiocarcinoma","volume":"11","author":"Wintachai","year":"2021","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.040_bib96","article-title":"Cell-free tumor DNA dominant clone allele frequency is associated with poor outcomes in advanced biliary cancers treated with platinum-based chemotherapy","volume":"6","author":"Uson Junior","year":"2022","journal-title":"JCO Precis Oncol"},{"issue":"9","key":"10.1016\/j.jhep.2026.03.040_bib97","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s43018-020-0096-5","article-title":"Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab","volume":"1","author":"Bratman","year":"2020","journal-title":"Nat Cancer"},{"issue":"16","key":"10.1016\/j.jhep.2026.03.040_bib98","article-title":"Liquid biopsy-based prediction of clinical benefit from immune checkpoint inhibitors in advanced biliary tract cancer","volume":"42","author":"Zhang","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2026.03.040_bib99","doi-asserted-by":"crossref","DOI":"10.1200\/PO.20.00178","article-title":"Noninvasive detection of polyclonal acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations","author":"Varghese","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.040_bib100","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/1078-0432.CCR-23-1317","article-title":"Landscape of clinical resistance mechanisms to FGFR inhibitors in FGFR2-altered cholangiocarcinoma","volume":"30","author":"Wu","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jhep.2026.03.040_bib101","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jhep.2023.10.041","article-title":"Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma","volume":"80","author":"DiPeri","year":"2024","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.040_bib102","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1136\/gutjnl-2021-325178","article-title":"Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures","volume":"71","author":"Arechederra","year":"2022","journal-title":"Gut"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.040_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100275","article-title":"Cell-free DNA from bile outperformed plasma as a potential alternative to tissue biopsy in biliary tract cancer","volume":"6","author":"Gou","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.jhep.2026.03.040_bib104","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102908","article-title":"Circulating blood biomarkers for minimal residual disease in hepatocellular carcinoma: a systematic review","volume":"135","author":"Galli","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jhep.2026.03.040_bib105","article-title":"Clinical utilization of testing for cell-free DNA in hepatocellular cancer","author":"Wang","year":"2026","journal-title":"Hepatology"},{"issue":"17","key":"10.1016\/j.jhep.2026.03.040_bib106","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1158\/1078-0432.CCR-18-3477","article-title":"Comprehensive liquid profiling of circulating tumor DNA and protein biomarkers in long-term follow-up patients with hepatocellular carcinoma","volume":"25","author":"Cai","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jhep.2026.03.040_bib107","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s13046-025-03379-7","article-title":"Extracellular vesicle digital scoring assay for assessment of treatment responses in hepatocellular carcinoma patients","volume":"44","author":"Zhao","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.jhep.2026.03.040_bib108","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jhep.2024.10.043","article-title":"Circulating tumor DNA status and dynamics predict recurrence in patients with resected extrahepatic cholangiocarcinoma","volume":"82","author":"Yoo","year":"2025","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.jhep.2026.03.040_bib109","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1038\/s41591-024-03254-6","article-title":"ctDNA-based molecular residual disease and survival in resectable colorectal cancer","volume":"30","author":"Nakamura","year":"2024","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.jhep.2026.03.040_bib110","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1158\/2159-8290.CD-25-0375","article-title":"Detection of cancers three years prior to diagnosis using plasma cell-free DNA","volume":"15","author":"Wang","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jhep.2026.03.040_bib111","article-title":"Hepatocellular carcinoma surveillance may be associated with potential psychological harms of in patients with cirrhosis","author":"Narasimman","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2026.03.040_bib112","article-title":"Financial burden of hepatocellular carcinoma screening in patients with cirrhosis","author":"Narasimman","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2026.03.040_bib113","article-title":"Value of HCC surveillance in a landscape of emerging surveillance options: perspectives of a multi-stakeholder modified delphi panel","author":"Singal","year":"2024","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2026.03.040_bib114","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1039\/C7NR08360B","article-title":"Technical challenges of working with extracellular vesicles","volume":"10","author":"Ramirez","year":"2018","journal-title":"Nanoscale"},{"issue":"6","key":"10.1016\/j.jhep.2026.03.040_bib115","first-page":"643","article-title":"Cost-effectiveness of a biomarker-based screening strategy for hepatocellular carcinoma in patients with cirrhosis","volume":"13","author":"Singal","year":"2024","journal-title":"Liver Cancer"},{"issue":"12","key":"10.1016\/j.jhep.2026.03.040_bib116","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17121928","article-title":"Roadmap for HCC surveillance and management in the asia pacific","volume":"17","author":"Kudo","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.jhep.2026.03.040_bib117","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.cgh.2023.01.039","article-title":"Breakthroughs in hepatocellular carcinoma therapies","volume":"21","author":"Singal","year":"2023","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826001959?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827826001959?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T16:53:27Z","timestamp":1789491207000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827826001959"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":117,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0168827826001959"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2026.03.040","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The future of blood-based biomarkers in liver cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2026.03.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association for the Study of the Liver. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}